Basel‑based Sandoz, once best known for low‑cost generic drugs such as Diovan and Lipitor, is shifting its focus toward the higher‑margin biosimilar market. The company says the move is intended to speed up revenue growth and improve profit margins.
Chief Executive Richard Saynor told investors on Tuesday that the firm expects a "golden decade" for biosimilars, signalling a long‑term commitment to the segment. The strategy follows Sandoz's broader effort to diversify beyond traditional generics and capture a larger share of the biologics‑copy market.
Sandoz, which was formerly a subsidiary of Novartis, did not provide specific financial targets but indicated that the biosimilar push will be a central driver of its future performance.
